Ex vivo-generated dendritic cells for clinicaltrials versus in Vivo targeting to dendritic cells: Critical issues

The Biology of Dendritic Cells and HIV Infection

Volumn , Issue , 2007, Pages 203-242

  Jacobs, Joannes F M ^a   Pereira, Cândida F ^a   Tacken, Paul J ^a   De Vries, I Jolanda M ^a   Punt, Cornelus J A ^a   Adema, Gosse J ^a   Figdor, Carl G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900155459     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-33785-2_6     Document Type: Chapter

References (157)

1. Abdel-Motal, U. M., Friedline, R., Poligone, B., Pogue-Caley, R. R., Frelinger, J. A., and Tisch, R. (2001). Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice. Clin. Immunol. 101:51-58.
2. Ackerman, A. L., and Cresswell, P. (2004). Cellular mechanisms governing crosspresentation of exogenous antigens. Nat. Immunol. 5:678-684.
3. Ackerman, A. L., Kyritsis, C., Tampe, R., and Cresswell, P. (2005). Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat. Immunol. 6:107-113.
4. Apostolopoulos, V., Pietersz, G. A., Loveland, B. E., Sandrin, M. S., and McKenzie, I. F. (1995). Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl. Acad. Sci. U. S. A. 92:10128-10132.
5. Apostolopoulos, V., Pietersz, G. A., Gordon, S., Martinez-Pomares, L., and McKenzie, I. F. (2000). Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur. J. Immunol. 30:1714-1723.
6. Arkema, A., Huckriede, A., Schoen, P., Wilschut, J., and Daemen, T. (2000). Induction of cytotoxic T lymphocyte activity by fusion-active peptidecontaining virosomes. Vaccine 18:1327-1333.
7. Arnaout, M. A. (1990). Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 75:1037-1050.
8. Arthur, J. F., Butterfield, L. H., Roth, M. D., Bui, L. A., Kiertscher, S. M., Lau, R., Dubinett, S., Glaspy, J., McBride, W. H., and Economou, J. S. (1997). A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4:17-25.
9. Arthur, L. O., Bess, J. W., Jr., Chertova, E. N., Rossio, J. L., Esser, M. T., Benveniste, R. E., Henderson, L. E., and Lifson, J. D. (1998). Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res. Hum. Retroviruses 14 Suppl. 3:S311-S319.
10. Banchereau, J., and Palucka, A. K. (2005). Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5:296-306.
11. Banchereau, J., and Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature 392:245-252.
12. Banchereau, J., Schuler-Thurner, B., Palucka, A. K., and Schuler, G. (2001). Dendritic cells as vectors for therapy. Cell 106:271-274.
13. Bell, D., Young, J. W., and Banchereau, J. (1999). Dendritic cells. Adv. Immunol. 72:255-324.
14. Belousova, N., Korokhov, N., Krendelshchikova, V., Simonenko, V., Mikheeva, G., Triozzi, P. L., Aldrich, W. A., Banerjee, P. T., Gillies, S. D., Curiel, D. T., and Krasnykh, V. (2003). Genetically targeted adenovirus vector directed to CD40-expressing cells. J. Virol. 77:11367-11377.
15. Binder, R. J., and Srivastava, P. K. (2005). Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat. Immunol. 6:593-599.
16. Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, M., Nussenzweig, M. C., and Steinman, R. M. (2002). Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196:1627-1638.
17. Bonifaz, L. C., Bonnyay, D. P., Charalambous, A., Darguste, D. I., Fujii, S., Soares, H., Brimnes, M. K., Moltedo, B., Moran, T. M., and Steinman, R. M. (2004). In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199:815-824.
18. Brown, K., Gao, W., Alber, S., Trichel, A., Murphey-Corb, M., Watkins, S. C., Gambotto, A., and Barratt-Boyes, S. M. (2003). Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J. Immunol. 171:6875-6882.
19. Bungener, L., Serre, K., Bijl, L., Leserman, L., Wilschut, J., Daemen, T., and Machy, P. (2002). Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20:2287-2295.
20. Caputo, A., Gavioli, R., and Ensoli, B. (2004). Recent advances in the development of HIV-1 Tat-based vaccines. Curr. HIV Res. 2:357-376.
21. Carbone, F. R., and Bevan, M. J. (1990). Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J. Exp. Med. 171:377-387.
22. Caux, C., Ait-Yahia, S., Chemin, K., de Bouteiller, O., Dieu-Nosjean, M. C., Homey, B., Massacrier, C., Vanbervliet, B., Zlotnik, A., and Vicari, A. (2000). Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin. Immunopathol. 22:345-369.
23. Chieppa, M., Bianchi, G., Doni, A., Del Prete, A., Sironi, M., Laskarin, G., Monti, P., Piemonti, L., Biondi, A., Mantovani, A., Introna, M., and Allavena, P. (2003). Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J. Immunol. 171:4552-4560.
24. Chougnet, C., Cohen, S. S., Kawamura, T., Landay, A. L., Kessler, H. A., Thomas, E., Blauvelt, A., and Shearer, G. M. (1999). Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. J. Immunol. 163:1666-1673.
25. Ciupitu, A. M., Petersson, M., ODonnell, C. L., Williams, K., Jindal, S., Kiessling, R., and Welsh, R. M. (1998). Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70?results in protective antiviral immunity and specific cytotoxic T lymphocytes. J. Exp. Med. 187:685-691.
26. Clay, T. M., Hobeika, A. C., Mosca, P. J., Lyerly, H. K., and Morse, M. A. (2001). Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 7:1127-1135.
27. Colino, J., and Snapper, C. M. (2003). Dendritic cells, new tools for vaccination. Microbes Infect. 5:311-319.
28. Cyster, J. G. (1999). Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J. Exp. Med. 189:447-450.
29. Daeron, M. (1997). Fc receptor biology. Annu. Rev. Immunol. 15:203-234.
30. De Smedt, T., Pajak, B., Muraille, E., Lespagnard, L., Heinen, E., De Baetselier, P., Urbain, J., Leo, O., and Moser, M. (1996). Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J. Exp. Med. 184:1413-1424.
31. de Vries, I. J., Eggert, A. A., Scharenborg, N. M., Vissers, J. L., Lesterhuis, W. J., Boerman, O. C., Punt, C. J., Adema, G. J., and Figdor, C. G. (2002). Phenotypical and functional characterization of clinical grade dendritic cells. J. Immunother. 25:429-438.
32. de Vries, I. J., Krooshoop, D. J., Scharenborg, N. M., Lesterhuis, W. J., Diepstra, J. H., Van Muijen, G. N., Strijk, S. P., Ruers, T. J., Boerman, O. C., Oyen, W. J., Adema, G. J., Punt, C. J., and Figdor, C. G. (2003a). Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63:12-17.
33. de Vries, I. J., Lesterhuis, W. J., Scharenborg, N. M., Engelen, L. P., Ruiter, D. J., Gerritsen, M. J., Croockewit, S., Britten, C. M., Torensma, R., Adema, G. J., Figdor, C. G., and Punt, C. J. (2003b). Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 9:5091-5100.
34. de Vries, I. J., Bernsen, M. R., Lesterhuis, W. J., Scharenborg, N. M., Strijk, S. P., Gerritsen, M. J., Ruiter, D. J., Figdor, C. G., Punt, C. J., and Adema, G. J. (2005). Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J. Clin. Oncol. 23:5779-5787.
35. Delneste, Y., Magistrelli, G., Gauchat, J., Haeuw, J., Aubry, J., Nakamura, K., Kawakami-Honda, N., Goetsch, L., Sawamura, T., Bonnefoy, J., and Jeannin, P. (2002). Involvement of LOX-1 in dendritic cell-mediated antigen crosspresentation. Immunity 17:353-362.
36. Deo, Y. M., Graziano, R. F., Repp, R., and van De Winkel, J. G. (1997). Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol. Today 18:127-135.
37. Deo, Y. M., Sundarapandiyan, K., Keler, T., Wallace, P. K., and Graziano, R. F. (1998). Bispecific molecules directed to the Fc receptor for IgA (Fc{alpha}RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J. Immunol. 160:1677-1686.
38. Ebensen, T., Paukner, S., Link, C., Kudela, P., de Domenico, C., Lubitz, W., and Guzman, C. A. (2004). Bacterial ghosts are an efficient delivery system for DNA vaccines. J. Immunol. 172:6858-6865.
39. Eko, F. O., Lubitz, W., McMillan, L., Ramey, K., Moore, T. T., Ananaba, G. A., Lyn, D., Black, C. M., and Igietseme, J. U. (2003). Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine 21:1694-1703.
40. el-Shami, K., Tirosh, B., Bar-Haim, E., Carmon, L., Vadai, E., Fridkin, M., Feldman, M., and Eisenbach, L. (1999). MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur. J. Immunol. 29:3295-3301.
41. Engering, A., Geijtenbeek, T. B. H., van Vliet, S. J., Wijers, M., van Liempt, E., Demaurex, N., Lanzavecchia, A., Fransen, J., Figdor, C. G., Piguet, V., and van Kooyk, Y. (2002). The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J. Immunol. 168:2118-2126.
42. Fanales-Belasio, E., Cafaro, A., Cara, A., Negri, D. R., Fiorelli, V., Butto, S., Moretti, S., Maggiorella, M. T., Baroncelli, S., Michelini, Z., Tripiciano, A., Sernicola, L., Scoglio, A., Borsetti, A., Ridolfi, B., Bona, R., Ten, H. P., Macchia, I., Leone, P., Pavone-Cossut, M. R., Nappi, F., Vardas, E., Magnani, M., Laguardia, E., Caputo, A., Titti, F., and Ensoli, B. (2002a). HIV-1 Tat-based vaccines: from basic science to clinical trials. DNA Cell Biol. 21:599-610.
43. Fanales-Belasio, E., Moretti, S., Nappi, F., Barillari, G., Micheletti, F., Cafaro, A., and Ensoli, B. (2002b). Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J. Immunol. 168:197-206.
44. Fantuzzi, L., Purificato, C., Donato, K., Belardelli, F., and Gessani, S. (2004). Human immunodeficiency virus type 1 gp120 induces abnormal maturation and functional alterations of dendritic cells: a novel mechanism for AIDS pathogenesis. J. Virol. 78:9763-9772.
45. Fayolle, C., Sebo, P., Ladant, D., Ullmann, A., and Leclerc, C. (1996). In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J. Immunol. 156:4697-4706.
46. Fayolle, C., Osickova, A., Osicka, R., Henry, T., Rojas, M. J., Saron, M. F., Sebo, P., and Leclerc, C. (2001). Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity. J. Virol. 75:7330-7338.
47. Feuerstein, B., Berger, T. G., Maczek, C., Roder, C., Schreiner, D., Hirsch, U., Haendle, I., Leisgang, W., Glaser, A., Kuss, O., Diepgen, T. L., Schuler, G., and Schuler-Thurner, B. (2000). A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J. Immunol. Methods 245:15-29.
48. Figdor, C. G., van Kooyk, Y., and Adema, G. J. (2002). C-type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev. Immunol. 2:77-84.
49. Figdor, C. G., de Vries, I. J., Lesterhuis, W. J., and Melief, C. J. (2004). Dendritic cell immunotherapy: mapping the way. Nat. Med. 10:475-480.
50. Frank, I., Piatak, M., Jr., Stoessel, H., Romani, N., Bonnyay, D., Lifson, J. D., and Pope, M. (2002). Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs. J. Virol. 76:2936-2951.
51. Frison, N., Taylor, M. E., Soilleux, E., Bousser, M. T., Mayer, R., Monsigny, M., Drickamer, K., and Roche, A. C. (2003). Oligolysine-based oligosaccharide clusters: selective recognition and endocytosis by the mannose receptor and dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin. J. Biol. Chem. 278:23922-23929.
52. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L., and Steinman, R. M. (2003). Activation of natural killer T cells by a-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198:267-279.
53. Fukasawa, M., Shimizu, Y., Shikata, K., Nakata, M., Sakakibara, R., Yamamoto, N., Hatanaka, M., and Mizuochi, T. (1998). Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes. FEBS Lett. 441:353-356.
54. Garcia, F., Lejeune, M., Climent, N., Gil, C., Alcami, J., Morente, V., Alos, L., Ruiz, A., Setoain, J., Fumero, E., Castro, P., Lopez, A., Cruceta, A., Piera, C., Florence, E., Pereira, A., Libois, A., Gonzalez, N., Guila, M., Caballero, M., Lomena, F., Joseph, J., Miro, J. M., Pumarola, T., Plana, M., Gatell, J. M., and Gallart, T. (2005). Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect. Dis. 191:1680-1685.
55. Gavioli, R., Gallerani, E., Fortini, C., Fabris, M., Bottoni, A., Canella, A., Bonaccorsi, A., Marastoni, M., Micheletti, F., Cafaro, A., Rimessi, P., Caputo, A., and Ensoli, B. (2004). HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J. Immunol. 173:3838-3843.
56. Geijtenbeek, T. B. H., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C. F., Adema, G. J., van Kooyk, Y., and Figdor, C. G. (2000). Identification of DCSIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100:575-585.
57. Geijtenbeek, T. B. H., Groot, P. C., Nolte, M. A., van Vliet, S. J., Gangaram-Panday, S. T., van Duijnhoven, G. C. F., Kraal, G., van Oosterhout, A. J. M., and van Kooyk, Y. (2002). Marginal zone macrophages express a murine homologue of DC-SIGN that captures blood-borne antigens in vivo. Blood 100:2908-2916.
58. Geijtenbeek, T. B. H., van Vliet, S. J., Koppel, E. A., Sanchez-Hernandez, M., Vandenbroucke-Grauls, C. M. J. E., Appelmelk, B., and van Kooyk, Y. (2003). Mycobacteria target DC-SIGN to suppress dendritic cell function. J. Exp. Med. 197:7-17.
59. Gieseler, R. K., Marquitan, G., Hahn, M. J., Perdon, L. A., Driessen, W. H., Sullivan, S. M., and Scolaro, M. J. (2004). DC-SIGN-specific liposomal targeting and selective intracellular compound delivery to human myeloid dendritic cells: implications for HIV disease. Scand. J. Immunol. 59:415-424.
60. Gilboa, E., and Vieweg, J. (2004). Cancer immunotherapy with mRNAtransfected dendritic cells. Immunol. Rev. 199:251-263.
61. Gorantla, S., Santos, K., Meyer, V., Dewhurst, S., Bowers, W. J., Federoff, H. J., Gendelman, H. E., and Poluektova, L. (2005). Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge. J. Virol. 79:2124-2132.
62. Gosselin, E. J., Wardwell, K., Gosselin, D. R., Alter, N., Fisher, J. L., and Guyre, P. M. (1992). Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J. Immunol. 149:3477-3481.
63. Griffiths, J. C., Berrie, E. L., Holdsworth, L. N., Moore, J. P., Harris, S. J., Senior, J. M., Kingsman, S. M., Kingsman, A. J., and Adams, S. E. (1991). Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant. J. Virol. 65:450-456.
64. Grousson, J., and Peguet-Navarro, J. (1998). Functional relevance of CD40 expression in human epidermis. Cell Biol. Toxicol. 14:345-350.
65. Guermonprez, P., Ladant, D., Karimova, G., Ullmann, A., and Leclerc, C. (1999). Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC class I antigen presentation pathway. J. Immunol. 162:1910-1916.
66. Guermonprez, P., Khelef, N., Blouin, E., Rieu, P., Ricciardi-Castagnoli, P., Guiso, N., Ladant, D., and Leclerc, C. (2001). The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the {{alpha}}M{beta}2 integrin (CD11b/CD18). J. Exp. Med. 193:1035-1044.
67. Guermonprez, P., Saveanu, L., Kleijmeer, M., Davoust, J., van Endert, P., and Amigorena, S. (2003). ER-phagosome fusion defines an MHC class I crosspresentation compartment in dendritic cells. Nature 425:397-402.
68. Guo, M., Gong, S., Maric, S., Misulovin, Z., Pack, M., Mahnke, K., Nussenzweig, M. C., and Steinman, R. M. (2000). A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum. Immunol. 61:729-738.
69. Haicheur, N., Bismuth, E., Bosset, S., Adotevi, O., Warnier, G., Lacabanne, V., Regnault, A., Desaymard, C., Amigorena, S., Ricciardi-Castagnoli, P., Goud, B., Fridman, W. H., Johannes, L., and Tartour, E. (2000). The B Subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J. Immunol. 165:3301-3308.
70. Hattori, Y., Kawakami, S., Suzuki, S., Yamashita, F., and Hashida, M. (2004). Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem. Biophys. Res. Commun. 317:992-999.
71. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V., Steinman, R. M., and Nussenzweig, M. C. (2001). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194:769-779.
72. Heijnen, I. A., Vugt, M. J., Fanger, N. A., Graziano, R. F., Wit, T. P., Hofhuis, F. M., Guyre, P. M., Capel, P. J., Verbeek, J. S., and Winkel, J. G. (1996). Antigen targeting to myeloid-specific human Fcgamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin. Invest. 97:331-338.
73. Hilkens, C. M., Kalinski, P., de Boer, M., and Kapsenberg, M. L. (1997). Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 90:1920-1926.
74. Honeychurch, J., Tutt, A. L., Valerius, T., Heijnen, I. A. F. M., van de Winkel, J. G. J., and Glennie, M. J. (2000). Therapeutic efficacy of Fcgamma RI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood 96:3544-3552.
75. Huang, X. L., Fan, Z., Zheng, L., Borowski, L., Li, H., Thomas, E. K., Hildebrand, W. H., Zhao, X. Q., and Rinaldo, C. R., Jr. (2003). Priming of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cell responses by dendritic cells loaded with HIV-1 proteins. J. Infect. Dis. 187:315-319.
76. Hudson, P. J., and Souriau, C. (2003). Engineered antibodies. Nat. Med. 9:129-134.
77. Jacewicz, M. S., Acheson, D. W., Mobassaleh, M., Donohue-Rolfe, A., Balasubramanian, K. A., and Keusch, G. T. (1995). Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. J. Clin. Invest. 96:1328-1335.
78. Jakob, T., Walker, P. S., Krieg, A. M., Udey, M. C., and Vogel, J. C. (1998). Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J. Immunol. 161:3042-3049.
79. Jenne, L., Schuler, G., and Steinkasserer, A. (2001). Viral vectors for dendritic cell-based immunotherapy. Trends Immunol. 22:102-107.
80. Jonuleit, H., Kuhn, U., Muller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J., and Enk, A. H. (1997). Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27:3135-3142.
81. Kalams, S. A., and Walker, B. D. (1998). The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188:2199-2204.
82. Kalams, S. A., Goulder, P. J., Shea, A. K., Jones, N. G., Trocha, A. K., Ogg, G. S., and Walker, B. D. (1999). Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 73:6721-6728.
83. Kalergis, A. M., and Ravetch, J. V. (2002). Inducing tumor immunity through the selective engagement of activating Fc{gamma} receptors on dendritic cells. J. Exp. Med. 195:1653-1659.
84. Kalinski, P., Hilkens, C. M., Wierenga, E. A., and Kapsenberg, M. L. (1999). T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 20:561-567.
85. Kappes, J. C., and Wu, X. (2001). Safety considerations in vector development. Somat. Cell Mol. Genet. 26:147-158.
86. Karanikas, V., Hwang, L. A., Pearson, J., Ong, C. S., Apostolopoulos, V., Vaughan, H., Xing, P. X., Jamieson, G., Pietersz, G., Tait, B., Broadbent, R., Thynne, G., and McKenzie, I. F. (1997). Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100:2783-2792.
87. Karp, C. L., Wysocka, M., Ma, X., Marovich, M., Factor, R. E., Nutman, T., Armant, M., Wahl, L., Cuomo, P., and Trinchieri, G. (1998). Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance. Eur. J. Immunol. 28:3128-3136.
88. Kawamura, T., Gatanaga, H., Borris, D. L., Connors, M., Mitsuya, H., and Blauvelt, A. (2003). Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells. J. Immunol. 170:4260-4266.
89. Keler, T., Guyre, P. M., Vitale, L. A., Sundarapandiyan, K., van De Winkel, J. G., Deo, Y. M., and Graziano, R. F. (2000). Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J. Immunol. 165:6738-6742.
90. Keler, T., Ramakrishna, V., and Fanger, M. W. (2004). Mannose receptor-targeted vaccines. Expert Opin. Biol. Ther. 4:1953-1962.
91. Kellermann, S. A., Hudak, S., Oldham, E. R., Liu, Y. J., and McEvoy, L. M. (1999). The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro-and in vivo-derived dendritic cells. J. Immunol. 162:3859-3864.
92. Kim, D. T., Mitchell, D. J., Brockstedt, D. G., Fong, L., Nolan, G. P., Fathman, C. G., Engleman, E. G., and Rothbard, J. B. (1997). Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J. Immunol. 159:1666-1668.
93. Kiyokawa, N., Taguchi, T., Mori, T., Uchida, H., Sato, N., Takeda, T., and Fujimoto, J. (1998). Induction of apoptosis in normal human renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2. J. Infect. Dis. 178:178-184.
94. Korokhov, N., de Gruijl, T. D., Aldrich, W. A., Triozzi, P. L., Banerjee, P. T., Gillies, S. D., Curiel, T. J., Douglas, J. T., Scheper, R. J., and Curiel, D. T. (2005a). High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol. Ther. 4:289-94.
95. Korokhov, N., Noureddini, S. C., Curiel, D. T., Santegoets, S. J., Scheper, R. J., and de Gruijl, T. D. (2005b). A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system. Mol. Pharm. 2:218-223.
96. LaCasse, E. C., Saleh, M. T., Patterson, B., Minden, M. D., and Gariepy, J. (1996). Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice. Blood 88:1561-1567.
97. Ladant, D., and Ullmann, A. (1999). Bordatella pertussis adenylate cyclase: a toxin with multiple talents. Trends Microbiol. 7:172-176.
98. Layton, G. T., Harris, S. J., Gearing, A. J., Hill-Perkins, M., Cole, J. S., Griffiths, J. C., Burns, N. R., Kingsman, A. J., and Adams, S. E. (1993). Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Tyvirus-like particles. J. Immunol. 151:1097-1107.
99. Lee, R. S., Tartour, E., van der, B. P., Vantomme, V., Joyeux, I., Goud, B., Fridman, W. H., and Johannes, L. (1998). Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the Bfragment of Shiga toxin. Eur. J. Immunol. 28:2726-2737.
100. Lindberg, A. A., Brown, J. E., Stromberg, N., Westling-Ryd, M., Schultz, J. E., and Karlsson, K. A. (1987). Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J. Biol. Chem. 262:1779-1785.
101. Lisziewicz, J., Trocio, J., Whitman, L., Varga, G., Xu, J., Bakare, N., Erbacher, P., Fox, C., Woodward, R., Markham, P., Arya, S., Behr, J. P., and Lori, F. (2005). DermaVir: a novel topical vaccine for HIV/AIDS. J. Invest. Dermatol. 124:160-169.
102. Lu, W., Arraes, L. C., Ferreira, W. T., and Andrieu, J. M. (2004). Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10:1359-1365.
103. Matzinger, P. (2002). The danger model: a renewed sense of self. Science 296:301-305.
104. Mitchell, D. A., and Nair, S. K. (2000). RNA-transfected dendritic cells in cancer immunotherapy. J. Clin. Invest. 106:1065-1069.
105. Moore, A., McGuirk, P., Adams, S., Jones, W. C., McGee, J. P., OHagan, D. T., and Mills, K. H. (1995). Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 13:1741-1749.
106. Moriwaki, H., Kume, N., Sawamura, T., Aoyama, T., Hoshikawa, H., Ochi, H., Nishi, E., Masaki, T., and Kita, T. (1998). Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 18:1541-1547.
107. Moron, V. G., Rueda, P., Sedlik, C., and Leclerc, C. (2003). In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J. Immunol. 171:2242-2250.
108. Moron, G., Dadaglio, G., and Leclerc, C. (2004). New tools for antigen delivery to the MHC class I pathway. Trends Immunol. 25:92-97.
109. Mosier, D. E. (2005). HIV-1 envelope evolution and vaccine efficacy. Curr. Drug Targets Infect. Disord. 5:171-177.
110. Mullins, D. W., Sheasley, S. L., Ream, R. M., Bullock, T. N., Fu, Y. X., and Engelhard, V. H. (2003). Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J. Exp. Med. 198:1023-1034.
111. Nehete, P. N., Nehete, B. P., Manuri, P., Hill, L., Palmer, J. L., and Sastry, K. J. (2005). Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model. Vaccine 23:2154-2159.
112. Nigou, J., Zelle-Rieser, C., Gilleron, M., Thurnher, M., and Puzo, G. (2001). Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor. J. Immunol. 166:7477-7485.
113. Ortiz-Stern, A., and Rosales, C. (2003). Cross-talk between Fc receptors and integrins. Immunol. Lett. 90:137-143.
114. Park, C. G., Takahara, K., Umemoto, E., Yashima, Y., Matsubara, K., Matsuda, Y., Clausen, B. E., Inaba, K., and Steinman, R. M. (2001). Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN. Int. Immunol. 13:1283-1290.
115. Pasquier, B., Launay, P., Kanamaru, Y., Moura, I. C., Pfirsch, S., Ruffie, C., Henin, D., Benhamou, M., Pretolani, M., Blank, U., and Monteiro, R. C. (2005). Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 22:31-42.
116. Pauza, C. D., Trivedi, P., Wallace, M., Ruckwardt, T. J., Le, B. H., Lu, W., Bizzini, B., Burny, A., Zagury, D., and Gallo, R. C. (2000). Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc. Natl. Acad. Sci. U. S. A. 97:3515-3519.
117. Pitcher, C. J., Quittner, C., Peterson, D. M., Connors, M., Koup, R. A., Maino, V. C., and Picker, L. J. (1999). HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5:518-525.
118. Pitisuttithum, P., Nitayaphan, S., Thongcharoen, P., Khamboonruang, C., Kim, J., de, S. M., Chuenchitra, T., Garner, R. P., Thapinta, D., Polonis, V., Ratto-Kim, S., Chanbancherd, P., Chiu, J., Birx, D. L., Duliege, A. M., McNeil, J. G., and Brown, A. E. (2003). Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J. Infect. Dis. 188:219-227.
119. Rayevskaya, M. V., and Frankel, F. R. (2001). Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes. J. Virol. 75:2786-2791.
120. Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Thery, C., Rescigno, M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., and Amigorena, S. (1999). Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:371-380.
121. Reis e Sousa. (2004). Activation of dendritic cells: translating innate into adaptive immunity. Curr. Opin. Immunol. 16:21-25.
122. Reis e Sousa, and Germain, R. N. (1995). Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J. Exp. Med. 182:841-851.
123. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., and Schuler, G. (1994). Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83-93.
124. Rose, N. F., Marx, P. A., Luckay, A., Nixon, D. F., Moretto, W. J., Donahoe, S. M., Montefiori, D., Roberts, A., Buonocore, L., and Rose, J. K. (2001). An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539-549.
125. Rossio, J. L., Esser, M. T., Suryanarayana, K., Schneider, D. K., Bess, J. W., Jr., Vasquez, G. M., Wiltrout, T. A., Chertova, E., Grimes, M. K., Sattentau, Q., Arthur, L. O., Henderson, L. E., and Lifson, J. D. (1998). Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72:7992-8001.
126. Rudolf, M. P., Fausch, S. C., Da Silva, D. M., and Kast, W. M. (2001). Human dendritic cells are activated by chimeric human papillomavirus type-16 viruslike particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 166:5917-5924.
127. Sallusto, F., and Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
128. Sapp, M., Engelmayer, J., Larsson, M., Granelli-Piperno, A., Steinman, R., and Bhardwaj, N. (1999). Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Immunol. Lett. 66:121-128.
129. Saron, M. F., Fayolle, C., Sebo, P., Ladant, D., Ullmann, A., and Leclerc, C. (1997). Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis?irus. Proc. Natl. Acad. Sci. U. S. A. 94:3314-3319.
130. Sawamura, T., Kume, N., Aoyama, T., Moriwaki, H., Hoshikawa, H., Aiba, Y., Tanaka, T., Miwa, S., Katsura, Y., Kita, T., and Masaki, T. (1997). An endothelial receptor for oxidized low-density lipoprotein. Nature 386:73-77.
131. Schirmbeck, R., and Reimann, J. (1996). Empty Ld molecules capture peptides from endocytosed hepatitis B surface antigen particles for major
132. Schlecht, G., Loucka, J., Najar, H., Sebo, P., and Leclerc, C. (2004). Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming. J. Immunol. 173:6089-6097.
133. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R., and Melief, C. J. (1998). T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-483.
134. Schuurhuis, D. H., Ioan-Facsinay, A., Nagelkerken, B., van Schip, J. J., Sedlik, C., Melief, C. J. M., Verbeek, J. S., and Ossendorp, F. (2002). Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J. Immunol. 168:2240-2246.
135. Sebo, P., Moukrim, Z., Kalhous, M., Schaft, N., Dadaglio, G., Sheshko, V., Fayolle, C., and Leclerc, C. (1999). In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying multiple copies of a viral CD8(+) T-cell epitope. FEMS Immunol. Med. Microbiol. 26:167-173.
136. Shen, L., van Egmond, M., Siemasko, K., Gao, H., Wade, T., Lang, M. L., Clark, M., van de Winkel, J. G. J., and Wade, W. F. (2001). Presentation of ovalbumin internalized via the immunoglobulin-A Fc receptor is enhanced through Fc receptor {gamma}-chain signaling. Blood 97:205-213.
137. Silvera, P., Richardson, M. W., Greenhouse, J., Yalley-Ogunro, J., Shaw, N., Mirchandani, J., Khalili, K., Zagury, J. F., Lewis, M. G., and Rappaport, J. (2002). Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J. Virol. 76:3800-3809.
138. Smith, D. C., Lord, J. M., Roberts, L. M., and Johannes, L. (2004). Glycosphingolipids as toxin receptors. Semin. Cell Dev. Biol. 15:397-408.
139. Soilleux, E. J., Morris, L. S., Leslie, G., Chehimi, J., Luo, Q., Levroney, E., Trowsdale, J., Montaner, L. J., Doms, R. W., Weissman, D., Coleman, N., and Lee, B. (2002). Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J. Leukoc. Biol. 71:445-457.
140. Sporri, R., and Reis e Sousa. (2005). Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol. 6:163-170.
141. Srivastava, P. (2002). Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2:185-194.
142. Steinman, R. M., and Dhodapkar, M. (2001). Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 94:459-473.
143. Sundarapandiyan, K., Keler, T., Behnke, D., Engert, A., Barth, S., Matthey, B., Deo, Y. M., and Graziano, R. F. (2001). Bispecific antibody-mediated destruction of Hodgkins lymphoma cells. J. Immunol. Methods 248:113-123.
144. Suzue, K., and Young, R. A. (1996). Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J. Immunol. 156:873-879.
145. Tacken, P. J., Hartshorn, K. L., White, M. R., van Kooten, C., van de Winkel, J. G. J., Reid, K. B. M., and Batenburg, J. J. (2004). Effective targeting of pathogens to neutrophils via chimeric surfactant protein D/anti-CD89 protein. J. Immunol. 172:4934-4940.
146. Tacken, P. J., de Vries, I. J., Gijzen, K., Joosten, B., Wu, D., Rother, R. P., Faas, S. J., Punt, C. J., Torensma, R., Adema, G. J., and Figdor, C. G. (2005). Effective induction of naive and recall T cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106:1278-1285.
147. Thompson, A. G., and Thomas, R. (2002). Induction of immune tolerance by dendritic cells: implications for preventative and therapeutic immunotherapy of autoimmune disease. Immunol. Cell Biol. 80:509-519.
148. Tillman, B. W., Gruijl, T. D., Bakker, S. A. L., Scheper, R. J., Pinedo, H. M., Curiel, T. J., Gerritsen, W. R., and Curiel, D. T. (1999). Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J. Immunol. 162:6378-6383.
149. van Broekhoven, C. L., Parish, C. R., Demangel, C., Britton, W. J., and Altin, J. G. (2004). Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 64:4357-4365.
150. Van den Herik-Oudijk, I., Capel, P. J., van der Bruggen, T., and van De Winkel, J. G. (1995). Identification of signaling motifs within human Fc gamma RIIa and Fc gamma RIIb isoforms. Blood 85:2202-2211.
151. van Spriel, A. B., van den Herik-Oudijk IE, van Sorge, N. M., Vile, H. A., van Strijp, J. A., and van De Winkel, J. G. (1999). Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils. J. Infect. Dis. 179:661-669.
152. Wallace, P. K., Tsang, K. Y., Goldstein, J., Correale, P., Jarry, T. M., Schlom, J., Guyre, P. M., Ernstoff, M. S., and Fanger, M. W. (2001). Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. J. Immunol. Methods 248:183-194.
153. Whiteside, T. L., and Odoux, C. (2004). Dendritic cell biology and cancer therapy. Cancer Immunol. Immunother. 53:240-248.
154. Wilson, N. S., and Villadangos, J. A. (2005). Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv. Immunol. 86:241-305.
155. Xin, K. Q., Hoshino, Y., Toda, Y., Igimi, S., Kojima, Y., Jounai, N., Ohba, K., Kushiro, A., Kiwaki, M., Hamajima, K., Klinman, D., and Okuda, K. (2003). Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 102:223-228.
156. Zhang, L., Tang, Y., Akbulut, H., Zelterman, D., Linton, P. J., and Deisseroth, A. B. (2003). An adenoviral vector cancer vaccine that delivers a tumorassociated antigen/CD40-ligand fusion protein to dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 100:15101-15106.
157. Zhou, Y., Bosch, M. L., and Salgaller, M. L. (2002). Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J. Immunother. 25:289-303.